Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Recruiting

Phase 1

ONC206Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Sponsor:

Chimerix

Code:

NCT04541082

Conditions

Central Nervous System Neoplasms

Glioblastoma

Gliosarcoma, Adult

Anaplastic Oligodendroglioma

Anaplastic Astrocytoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ONC206

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by Chimerix on 2025-02-07.